Journal
BLOOD ADVANCES
Volume 6, Issue 1, Pages 238-247Publisher
ELSEVIER
DOI: 10.1182/bloodadvances.2021004292
Keywords
-
Categories
Ask authors/readers for more resources
Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) significantly impact the prognosis of acute myeloid leukemia (AML). Particularly, CEBPAmu in the basic leucine zipper domain (bZIP) is strongly associated with a favorable prognosis and can serve as a potent marker for AML prognosis. This finding has implications for treatment stratification and the development of targeted therapeutic approaches in CEBPA-mutated AML.
Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) are found in 10% to 15% of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPAdm) is associated with a favorable prognosis; however, single-mutated CEBPA (CEBPAsm) does not seem to improve prognosis. We investigated CEBPAmu for prognosis in 1028 patients with AML, registered in the Multi-center Collaborative Program for Gene Sequencing of Japanese AML. It was found that CEBPAmu in the basic leucine zipper domain (bZIP) was strongly associated with a favorable prognosis, but CEBPAmu out of the bZIP domain was not. The presence of CEBPAmu in bZIP was a strong indicator of a higher chance of achieving complete remission (P < .001), better overall survival (OS; P < .001) and a lower risk of relapse (P < .001). The prognostic significance of CEBPAmu in bZIP was also observed in the subgroup with CEBPAsm (all patients: OS, P = .008; the cumulative incidence of relapse, P = .063; patients aged <_70 years and with intermediate-risk karyotype: OS, P = .008; cumulative incidence of relapse, P = .026). Multivariate analysis of 744 patients aged <_70 years showed that CEBPAmu in bZIP was the most potent predictor of OS (hazard ratio, 0.3287; P < .001). CEBPAdm was validated as a cofounding factor, which was overlapping with CEBPAmu in bZIP. In summary, these findings indicate that CEBPAmu in bZIP is a potent marker for AML prognosis. It holds potential in the refinement of treatment stratification and the develop-ment of targeted therapeutic approaches in CEBPA-mutated AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available